Screening for inherited metabolic disorders in patients with psychotic disorders
Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.
This study is testing whether a special test can find hidden metabolic disorders in adults with psychotic disorders to help improve their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Trial ID | NCT05206292 on ClinicalTrials.gov |
What this trial studies
This study aims to screen adult patients with psychotic disorders for hereditary metabolic diseases related to sulfur amino acid metabolism using a sulfitest. Given the complexity of identifying such disorders among psychotic patients, this research seeks to determine the prevalence of these conditions in this population. The study is motivated by recent findings of a new hereditary metabolic disease linked to psychotic disorders, which could lead to significant changes in patient management if identified. By focusing on patients without known organic causes for their psychosis, the study hopes to uncover previously undiagnosed metabolic disorders.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with a psychotic disorder and without a known organic etiology.
Not a fit: Patients with known organic causes for their psychotic disorder or those who are minors, pregnant, or under legal protection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and treatment of treatable metabolic disorders in patients with psychotic disorders.
How similar studies have performed: While the approach of screening for metabolic disorders in psychotic patients is relatively novel, previous studies have indicated potential success in identifying treatable conditions in similar populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female 18 years of age and older, * Followed for a psychotic disorder, * With no known organic etiology for the psychotic disorder, * Not having formulated its opposition to participation in the study (or his/her tutor/curator), * Affiliated with the social security system. Exclusion Criteria: * Patients protected by law (minors, pregnant or breastfeeding women, deprived of liberty or hospitalized under constraint, under administrative or judicial supervision) except patients under tutorship or curatorship.
Where this trial is running
Grenoble
- CHU Grenoble Alpes — Grenoble, France (Recruiting)
Study contacts
- Principal investigator: Gérard Besson — University Hospital, Grenoble
- Study coordinator: Gauthier Willaume
- Email: gwillaume@chu-grenoble.fr
- Phone: +33 4 76 76 57 92
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.